세포의 밀착이음 강화 방법
    1.
    发明公开
    세포의 밀착이음 강화 방법 有权
    增强细胞屏障功能的方法

    公开(公告)号:KR1020140056517A

    公开(公告)日:2014-05-12

    申请号:KR1020120120159

    申请日:2012-10-29

    Abstract: The present invention relates to a method for reinforcing a barrier function of a cell, by reinforcing the function or increasing gene expression by having an NADPH-quinone-oxidoreductase-1 (NQO1) gene or a protein expressed therefrom, as a target molecule. More specifically, the present invention is based on a cell barrier function relating to worsening of an inflammation of a large intestine epithelial cell of a human or a mammal, and an NQO1 gene adjusting the cell barrier function, to suppress the worsening of the inflammation caused by a loss of the barrier function of the large intestine epithelial cell and provide a treatment for effectively treating various acute and chronic enteritis diseases.

    Abstract translation: 本发明涉及通过使NADPH-醌 - 氧化还原酶-1(NQO1)基因或其表达的蛋白质作为靶分子来增强功能或增加基因表达来增强细胞的屏障功能的方法。 更具体地,本发明是基于与人或哺乳动物的大肠上皮细胞的炎症恶化有关的细胞屏障功能和调节细胞屏障功能的NQO1基因,以抑制炎症恶化 通过损失大肠上皮细胞的屏障功能,并提供有效治疗各种急性和慢性肠炎疾病的治疗方法。

    세포의 밀착이음 강화 방법
    2.
    发明授权
    세포의 밀착이음 강화 방법 有权
    增强细胞紧密连接的方法

    公开(公告)号:KR101507358B1

    公开(公告)日:2015-04-08

    申请号:KR1020120120159

    申请日:2012-10-29

    Abstract: 본발명은세포의밀착이음강화방법에관한것이다. 이는 NADPH 퀴논옥시도리덕타제-1(NQO1, NADPH-quinone-oxidoreductase-1) 유전자또는그로부터발현되는단백질을목적분자로하여그 기능을강화하거나또는유전자발현율을높이는것으로이루어질수 있다. 구체적으로인간이나포유동물의대장의상피세포의염증반응이악화되는것은세포장벽기능이관련되어있으며, 또한세포장벽기능을 NQO1 유전자가조절한다는것에기초하여, 본발명은대장의상피세포의장벽기능소실로부터발생할수 있는염증반응의악화를억제함으로써각종급만성장염질환을효과적으로치료할수 있는치료법을제공할수 있다.

    룸브리쿠신 펩타이드를 유효성분으로 함유하는 신경세포 성장 조절용 조성물
    3.
    发明公开
    룸브리쿠신 펩타이드를 유효성분으로 함유하는 신경세포 성장 조절용 조성물 有权
    用于控制含有胡萝卜素肽的神经细胞生长的组合物

    公开(公告)号:KR1020150050644A

    公开(公告)日:2015-05-11

    申请号:KR1020130129442

    申请日:2013-10-29

    CPC classification number: A61K38/08

    Abstract: 본발명은룸브리쿠신펩타이드를유효성분으로함유하는신경세포성장조절용조성물에관한것이다. 본발명에서는서열번호 1의아미노산배열을가지며, 신경세포의성장을촉진하는조절자인룸브리쿠신펩타이드(lumbricusin peptide)를유효성분으로함유하는신경세포성장조절용조성물을제공하는것이특징이다. 본발명에의해, 별다른부작용없이신경세포성장과증식을촉진하거나세포사멸과정을억제할수 있는새로운신경세포성장조절용조성물이제공될수 있어, 퇴행성신경질환의치료를위한비용이저렴하면서부작용이없는새로운치료제의개발가능성을제공한다는등의현저한효과를제공할수 있게된다.

    Abstract translation: 本发明涉及一种用于控制神经细胞生长的组合物,其含有作为促进神经细胞生长的控制剂的作为活性成分的,包含SEQ ID NO:1的氨基酸序列的lumbricusin肽。根据 本发明提供了用于控制新神经细胞生长以促进神经细胞生长和增殖并抑制凋亡过程而没有特别副作用的组合物,以及对新药治疗神经变性疾病的发展潜力的显着影响 成本较低,无副作用。

    면역세포 억제용 조성물
    4.
    发明公开
    면역세포 억제용 조성물 无效
    用于抑制免疫活性活性的组合物

    公开(公告)号:KR1020130057012A

    公开(公告)日:2013-05-31

    申请号:KR1020110122713

    申请日:2011-11-23

    Abstract: PURPOSE: A composition for suppressing immunocytes containing a coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient is provided to significantly suppress activation of macrophage without side effects such as cytotoxicity, and to develop a novel therapeutic agent for treating immune diseases including arteriosclerosis and rheumatoid arthritis. CONSTITUTION: A composition for suppressing immunocytes contains a coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient. The derivative is a regulator which suppresses activation of immunocytes. The immunocytes are macrophage. The derivative is D-type and is derived from an insect. The derivative is used for treating immune diseases including arteriosclerosis and rheumatoid arthritis.

    Abstract translation: 目的:提供用于抑制作为活性成分的CopA3(9-聚体二硫化物二聚体)的Copris3(9-聚体二硫化物二聚体)作为活性成分的抑制免疫细胞的组合物,以显着抑制巨噬细胞的活化而无副作用,例如细胞毒性,并开发新的治疗剂 免疫疾病,包括动脉硬化和类风湿性关节炎。 构成:用于抑制免疫细胞的组合物含有共感染肽衍生物CopA3(9-聚体二硫化物二聚体)作为活性成分。 该衍生物是抑制免疫细胞活化的调节剂。 免疫细胞是巨噬细胞。 衍生物是D型,衍生自昆虫。 该衍生物用于治疗包括动脉硬化和类风湿性关节炎在内的免疫疾病。

    급성위막성대장염 치료용 조성물
    5.
    发明授权
    급성위막성대장염 치료용 조성물 有权
    治疗COPA3肽类似物的分离方法用于C.多发性纤维蛋白溶解性和一般性胃肠炎

    公开(公告)号:KR101021226B1

    公开(公告)日:2011-03-11

    申请号:KR1020100037204

    申请日:2010-04-22

    CPC classification number: A61K38/08

    Abstract: PURPOSE: A composition containing coprisin peptide derivative CopA3(HL) for treating Pseudomembranous colitis is provided to prevent antibiotics effect to helpful microbes such as Bifidobacterium and Lactobacillus. CONSTITUTION: A composition for treating Pseudomembranous colitis contains coprisin peptide derivative CopA3(HL) as an active ingredient. The coprisin peptide derivative CopA3(HL) has an amino acid sequence(L-L-C-I-A-L-R-K-K). The coprisin peptide derivative suppresses Clostrdium difficile in the large intestine. The coprisin peptide derivative CopA3(HL) is D-type.

    Abstract translation: 目的:提供含有用于治疗假膜性结肠炎的复合蛋白肽衍生物CopA3(HL)的组合物,以防止抗生素对有益微生物如双歧杆菌和乳杆菌的作用。 构成:用于治疗假膜性结肠炎的组合物含有作为活性成分的共感染肽衍生物CopA3(HL)。 共聚蛋白肽衍生物CopA3(HL)具有氨基酸序列(L-L-C-I-A-L-R-K-K)。 共感染肽衍生物抑制大肠中的艰难梭菌(Clostrdium difficile)。 共聚蛋白肽衍生物CopA3(HL)是D型。

    대장상피세포 장벽기능 강화를 위한 HDAC6 효소 억제제용 조성물
    8.
    发明授权
    대장상피세포 장벽기능 강화를 위한 HDAC6 효소 억제제용 조성물 有权
    用于增强肠上皮细胞屏障功能的HDAC6酶抑制剂的组合物

    公开(公告)号:KR101734072B1

    公开(公告)日:2017-05-12

    申请号:KR1020150158110

    申请日:2015-11-11

    Abstract: 본발명은대장상피세포장벽기능강화를위한 HDAC6 효소억제제용조성물에관한것이다. 본발명은, 불린단백질의탈아세틸화를막아대장상피세포장벽기능강화를위한, HDAC6 효소억제제용조성물로서, 아세트산칼륨(potassium acetate)이유효성분으로포함되는것이특징이다. 본발명에의해, 세포독성은낮음과동시에미세소관형성을촉진할수 있으면서대장내 상피세포들의세포골격계가강화되어장벽기능이증대되는효과를나타내는대장상피세포장벽기능강화를위한 HDAC6 효소억제제용조성물이제공된다.

    Abstract translation: 本发明涉及用于增强肠上皮细胞屏障功能的HDAC6酶抑制剂的组合物。 本发明中,作为一个块的蛋白质的脱乙酰基作用称为用于增强上皮细胞的屏障功能结肠,为HDAC6抑制剂的组合物,将被包括在所述原因晓星乙分钟钾(乙酸钾)的特征。 根据本发明,所述细胞毒性是低的,并在同一时间对HDAC6抑制剂组合物,同时能够促进用于示出所述效果增强屏障结肠上皮细胞的功能微管形成被增强我的上皮结肠的细胞骨架系统,其屏障功能是增加的 它提供。

Patent Agency Ranking